Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App boosts PrEP use among men and transgender women at high HIV risk

NCT ID NCT06159582

Prevention Sponsor: San Diego State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a mobile app called eSTEP designed to help men who have sex with men and transgender women at high risk for HIV start and continue taking PrEP, a daily pill or injection that prevents HIV. 113 participants were randomly assigned to use the app plus usual care or just usual care. The app provided tailored support and reminders. Results showed that more people in the app group started PrEP and stayed on it over 24 weeks compared to those receiving usual care alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mobile app (eSTEP)
What this could lead to
If effective, this app could help more people at high risk for HIV start and stick with PrEP, reducing new infections.
What could go wrong
This was a small pilot study (113 people) and the app may not work as well in larger, more diverse groups. The results are promising but need confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

113 people

The number who actually took part.

Started

Apr 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * Assigned male sex at birth * Current male \& MSM identity OR transfeminine (woman, transgender woman, or non-binary) identification * Self-reported HIV-negative status * English-speaking (since the pilot intervention will be developed in English) * Owner of an Android or iPhone mobile device and access to this phone during the 6-month study. * Willingness and ability to attend HIV prevention visits at the HIV treatment and prevention clinic. * Consent to allow study team access to study-relevant PHI * Eligible for PrEP following CDC guidelines (in the past 6 months had a sexual partner with HIV with unknown or detectable viral load, inconsistently used condoms, and/or was diagnosed with a sexually transmitted infection) * Has never used PrEP or has not used PrEP in the past 3 months Exclusion Criteria: * Was a Community Advisory Board Member or participant in the eSTEP focus groups * Assigned female or intersex at birth * Living with HIV * Already taking PrEP * Under 18 years old * Does not own a mobile phone * Does not speak or read English (since the pilot intervention will be developed in English)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-exposure prophylaxis (PREP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-exposure prophylaxis (PREP)

Contacts and locations

Locations

  • San Diego State University - Department of Psychology

    San Diego, California, 92120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.